文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

抑制免疫抑制剂:癌症中髓源抑制性细胞的治疗靶点。

Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

机构信息

From the *Department of Microbiology and Immunology and †Division of Hematology and Medical Oncology, Department of Medicine, James Graham Brown Cancer Center, University of Louisville, Louisville, KY.

出版信息

Cancer J. 2013 Nov-Dec;19(6):490-501. doi: 10.1097/PPO.0000000000000006.


DOI:10.1097/PPO.0000000000000006
PMID:24270348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3902636/
Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with suppressive properties that preferentially expand in cancer. Myeloid-derived suppressor cells mainly suppress T-cell proliferation and cytotoxicity, inhibit natural killer cell activation, and induce the differentiation and expansion of regulatory T cells. The wide spectrum of MDSC suppressive activity in cancer and its role in tumor progression have rendered these cells a promising target for effective cancer immunotherapy. In this review we briefly discuss the origin of MDSCs and their main mechanisms of suppression and focus more on the approaches developed up to date targeting of MDSCs in tumor-bearing animals and cancer patients.

摘要

髓源性抑制细胞(MDSCs)是一群具有抑制特性的未成熟髓系细胞,在癌症中优先扩增。髓源性抑制细胞主要抑制 T 细胞的增殖和细胞毒性,抑制自然杀伤细胞的激活,并诱导调节性 T 细胞的分化和扩增。MDSC 在癌症中的广泛抑制活性及其在肿瘤进展中的作用,使这些细胞成为癌症免疫治疗的一个有前途的靶点。在这篇综述中,我们简要讨论了 MDSC 的起源及其主要的抑制机制,并更侧重于迄今为止针对荷瘤动物和癌症患者的 MDSC 靶向治疗方法。

相似文献

[1]
Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Cancer J. 2013

[2]
Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy.

Curr Top Med Chem. 2017

[3]
The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells.

Immunology. 2013-2

[4]
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Adv Cancer Res. 2015

[5]
Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.

Clin Immunol. 2016-10-21

[6]
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.

Cells. 2021-5-11

[7]
MDSCs in cancer: Conceiving new prognostic and therapeutic targets.

Biochim Biophys Acta. 2016-1

[8]
Myeloid-derived suppressor cells: linking inflammation and cancer.

J Immunol. 2009-4-15

[9]
The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion.

Front Immunol. 2020

[10]
Myeloid-derived suppressor cells in breast cancer.

Breast Cancer Res Treat. 2013-7-5

引用本文的文献

[1]
CAR-T therapy-based innovations in the enhancement of contemporary anti-tumor therapies.

Front Immunol. 2025-7-2

[2]
Role of Nutrients Regulating Myeloid Derived Suppressor Cells in Cancer: A Scoping Review.

Curr Issues Mol Biol. 2024-8-23

[3]
Mathematical modeling indicates that regulatory inhibition of CD8+ T cell cytotoxicity can limit efficacy of IL-15 immunotherapy in cases of high pre-treatment SIV viral load.

PLoS Comput Biol. 2023-8

[4]
Single-cell transcriptome analysis reveals the clinical implications of myeloid-derived suppressor cells in head and neck squamous cell carcinoma.

Pathol Oncol Res. 2023

[5]
Initial Myeloid Cell Status Is Associated with Clinical Outcomes of Renal Cell Carcinoma.

Biomedicines. 2023-4-27

[6]
Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation.

Front Immunol. 2022

[7]
G-CSF/GM-CSF-induced hematopoietic dysregulation in the progression of solid tumors.

FEBS Open Bio. 2022-7

[8]
Inflammation and tumor progression: signaling pathways and targeted intervention.

Signal Transduct Target Ther. 2021-7-12

[9]
Penetrable Nanoplatform for "Cold" Tumor Immune Microenvironment Reeducation.

Adv Sci (Weinh). 2020-7-29

[10]
Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

J Clin Invest. 2020-12-1

本文引用的文献

[1]
The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils.

J Exp Med. 2013-7-29

[2]
Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.

Cancer Res. 2013-7-18

[3]
Origin of monocytes and macrophages in a committed progenitor.

Nat Immunol. 2013-6-30

[4]
Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.

Blood. 2013-6-11

[5]
Long-term response to sunitinib therapy for metastatic renal cell carcinoma.

Clin Genitourin Cancer. 2013-5-24

[6]
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy.

Ann N Y Acad Sci. 2013-5

[7]
Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.

Cancer Res. 2013-4-30

[8]
Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Cancer Immunol Immunother. 2013-4-16

[9]
Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.

Int J Cancer. 2013-4-13

[10]
Effects of HDM2 antagonism on sunitinib resistance, p53 activation, SDF-1 induction, and tumor infiltration by CD11b+/Gr-1+ myeloid derived suppressor cells.

Mol Cancer. 2013-3-5

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索